Elon Musk has unveiled plans for 'Terafab,' a massive semiconductor manufacturing joint venture between Tesla and SpaceX. While the project aims to secure supply chains through vertical integration, analysts warn that the cost could reach into the trillions of dollars. This unprecedented price tag is raising significant questions regarding investor faith in Musk's ability to fund and execute such large-scale projects. The prospect of extreme capital expenditures (CAPEX) introduces substantial financial uncertainty for Tesla shareholders. Market experts suggest that the potential for share dilution to fund this venture could weigh heavily on the stock's long-term valuation. Consequently, the plan is being viewed with caution as it tests the limits of Tesla's capital allocation strategy.

Sources:marketwatch.commarketwatch.comaxios.comtechcrunch.comelectrek.cofortune.commarketwatch.comnewatlas.comtheregister.com